ClinicalTrials.gg
RecruitingNCT07457138LoBHeSUpdated Mar 17, 2026

Lombard Cohort of Brain Health Services

An observational study in Subjective Cognitive Decline (SCD), Functional Cognitive Disorder and Alzheimer's Disease, sponsored by University of Milano Bicocca. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by University of Milano Bicocca · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Planned enrollment
8th of 36
1,000 · median 273
Started
2026
with 10 others
Observational
36 of 206
18 open now
Primary completion
2028-02
later than 45 of 71 live
Registered
194th of 206
by date

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 8th largest by planned enrollment of the 36 observational ones that give a count, is one of 11 that started in 2026, is one of 36 observational ones, reaches primary completion later than 45 of the 71 other live ones, and was the 194th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

The goal of this multicenter prospective observational cohort study is to better understand the clinical, neuropsychological, and biological characteristics of individuals attending Brain Health Services (BHS) in the Lombardy region. The study focuses on adults with subjective cognitive decline (SCD), functional cognitive disorder (FCD), or "well worried" individuals without objective cognitive impairment.

The main questions it aims to answer are:

  • What clinical, cognitive, and biological differences exist between individuals who are positive versus negative for Alzheimer's disease (AD) plasma biomarkers (p-tau217) at baseline?
  • What factors predict positivity to AD biomarkers at baseline?
  • How does communication of biomarker results (risk disclosure) affect psychological well-being shortly after receiving results?
  • What factors predict longitudinal changes in AD biomarkers over 5 years?
  • Do baseline biomarkers predict the development of mild cognitive impairment (MCI) or dementia during follow-up?

Participants will:

  • Undergo standard clinical evaluation at their local BHS
  • Provide blood samples for plasma biomarker analysis (e.g., p-tau217, GFAP, NfL, ApoE)
  • Undergo neuropsychological testing and cognitive screening
  • Complete questionnaires assessing psychological impact and risk perception (before and after biomarker disclosure)
  • Undergo additional center-specific procedures when clinically indicated (e.g., MRI, lumbar puncture, polysomnography)
  • Be followed annually for 5 years

The study plans to enroll approximately 1000 participants across multiple BHS in Lombardy and will follow them for a total duration of 7 years. The results will help clarify the role of biomarkers in early cognitive complaints and support the development of preventive strategies within BHS.

03

Conditions studied

  • Subjective Cognitive Decline (SCD)
  • Functional Cognitive Disorder
  • Alzheimer's Disease
  • Brain Health

Browse trials for

Keywords

  • Brain Health Services
  • Subjective Cognitive Decline
  • Alzheimer's Disease
  • Functional Cognitive Disorder
  • pTau-217
  • GFAP
  • NfL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects accessing BHS in Lombardy with SCD, FCD or "well worried" individuals without objective cognitive impairment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years)
  • Diagnosis of SCD, FCD, or "well worried" individuals without objective cognitive impairment
  • Evaluation at one of the Lombardy BHS
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of mild cognitive impairment or dementia at baseline visit
  • Enrollment in another interventional study with an expected effect on cognition
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Brain Health Service users

    Adults with either Subjective Cognitive Decline, Functional Cognitive Disorder or Well Worried accessing Brain Health Services for dementia risk assessment

06

What researchers measure

Primary outcomes

  1. Clinical, neuropsychological, and biological patterns associated with AD plasma biomarker positivity at baseline

    Identification of multivariate patterns (e.g., principal component analysis and clustering methods) differentiating individuals positive versus negative for Alzheimer's disease plasma biomarker (p-tau217) at baseline, based on demographic, clinical, neuropsychological, radiological, and biological variables.

    Time frame: Baseline (first visit at Brain Health Service)

Secondary outcomes

  1. Psychological impact of biomarker disclosure at1 week

    Change in psychological measures (Hospital Anxiety and Depression Scale - HADS; Impact of Event Scale - Revised - IES-R) before and one week after communication of biomarker results.

    Time frame: Baseline (pre-disclosure) and 1 week after biomarker disclosure

  2. Predictors of AD plasma biomarker positivity at baseline

    Identification of demographic, clinical, neuropsychological, and radiological predictors of baseline AD plasma biomarker positivity, assessed using logistic and regression models.

    Time frame: Baseline

  3. Predictors of longitudinal changes in AD biomarkers

    Identification of clinical, neuropsychological, and radiological predictors of longitudinal changes in plasma AD biomarkers over time using linear mixed-effects models.

    Time frame: Baseline through 5 years follow-up

Other outcomes

  1. Predictors of conversion to MCI or dementia

    Evaluation of clinical, biological (plasma and CSF biomarkers), radiological, and neuropsychological predictors of progression to mild cognitive impairment (MCI) or dementia using survival analysis (Kaplan-Meier and Cox models).

    Time frame: Baseline through 5 years follow-up

  2. Predictive performance of plasma biomarkers for AD diagnosis

    Assessment of diagnostic accuracy of plasma biomarkers (neurodegeneration, Alzheimer's pathology, neuroinflammation markers) in predicting CSF biomarker positivity for AD using logistic regression models and ROC curve analysis.

    Time frame: Baseline

07

Study locations

3 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications (including demographic, clinical, neuropsychological, biomarker, and imaging-derived variables) will be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Beginning 12 months after primary publication and ending 5 years thereafter.

Access criteria: Data will be available to researchers who provide a methodologically sound proposal, subject to approval by the study steering committee and signing of a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 24 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 9, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Feb 1, 2033
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457138
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Feb 1, 2026
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2033 (estimated)
Last update
Mar 17, 2026

Study contacts

Federico Emanuele Pozzi, MD
Contact
federicoemanuele.pozzi@gmail.com
+393494113421
Carlo Ferrarese, MD, PhD
study chair · University of Milano Bicocca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion